HighTower Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

HighTower Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-20,000	Closed	-$2K	–	2524
2020 Q1	$2K	Buy	20,000 +4,800	+32%	+$35.6K	﹤0.01%	2183
2019 Q4	$13K	Buy	15,200 +11,200	+280%	+$103K	﹤0.01%	2190
2019 Q3	$3K	Buy	+4,000	New	+$44.9K	﹤0.01%	2352
2019 Q1	–	Sell	-2,000	Closed	-$13K	–	2413
2018 Q4	$13K	Hold	2,000	–	–	﹤0.01%	2115
2018 Q3	$13K	Buy	+2,000	New	+$30.4K	﹤0.01%	2193

Other funds holding SGMO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

HighTower Advisors's SGMO Position: Q1 2026 in Review

HighTower Advisors increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 0.29% in Q1 2026, buying an estimated $806 and bringing the position to 706,481 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #3530.

HighTower Advisors first reported a position in SGMO in Q4 2014 and has held it in 45 quarters since. The position peaked at $7.14M in Q4 2021. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

HighTower Advisors held 706,481 shares of SANGAMO THERAPEUTICS INC worth $174K as of Q1 2026.
HighTower Advisors bought 2,025 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $806.
SANGAMO THERAPEUTICS INC made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3530 holding.
HighTower Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and has held it in 45 quarters since.
HighTower Advisors's SANGAMO THERAPEUTICS INC position peaked at $7.14M in Q4 2021.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.